Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Katie Gatwood"'
Autor:
Karen B. Farris, Tiffany Cadwallader, Joel Farley, Katie Gatwood, Emily Mackler, Justin Gatwood
Publikováno v:
Exploratory Research in Clinical and Social Pharmacy, Vol 7, Iss , Pp 100163- (2022)
Improvements in chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) treatment options have increased the 5-year survival rates for patients with these hematologic malignancies. In addition to cancer managemen
Externí odkaz:
https://doaj.org/article/237f7e197e3947ce98efe02be01e0456
Publikováno v:
Clinical Hematology International, Vol 1, Iss 1 (2019)
Externí odkaz:
https://doaj.org/article/f0e36653390e4fae85278f06055da612
Autor:
Justin Gatwood, Ankur Dashputre, Abhijeet Rajpurohit, Katie Gatwood, Emily Mackler, Leah Wallace, Karen Farris, Amna Rizvi-Toner, Joel Farley
Publikováno v:
JCO Oncology Practice. 18:e1475-e1483
PURPOSE: Increased use of oral anticancer agents (OAAs) has empowered adults with multiple myeloma (MM) to manage their oncolytic therapy, but such a shift may result in issues with medication use, particularly among patients being concurrently treat
Publikováno v:
Bone Marrow Transplantation. 58:219-221
Autor:
Justin Gatwood, Ankur Dashputre, Abhijeet Rajpurohit, Katie Gatwood, Emily Mackler, Leah Wallace, Karen Farris, Amna Rizvi-Toner, Joel Farley
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311719
Introduction Increased use of oral anticancer agents (OAAs) has empowered adults with chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML) to manage their therapy, but this shift may complicate medication use, particularly among
Autor:
Ameet Patel, Karina Wilkerson, Heidi Chen, Deva Sharma, Michael Byrne, Jennifer Green, Salyka Sengsayadeth, Bhagirathbhai Dholaria, Bipin Savani, Wichai Chinratanalab, Reena Jayani, Katie Gatwood, Brian G. Engelhardt, Carrie Kitko, James Connelly, Adetola Kassim
Publikováno v:
Transplantation and Cellular Therapy. 28:277.e1-277.e6
Thrombosis is a recognized complication in sickle cell disease (SCD). Allogeneic hematopoietic cell transplantation (allo-HCT) remains the sole curative option for patients with severe SCD phenotypes. Data describing the effects of allo-HCT on recurr